East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Carbidopa and Levodopa Tablets USP, 10mg/100mg, 25mg/100mg, and 25mg/250mg. Aurobindo Pharma’s Carbidopa and Levodopa Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), SINEMET® Tablets, manufactured by ORGANON, LLC.

Carbidopa and Levodopa Tablets are indicated for:

• The treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.